<DOC>
	<DOCNO>NCT01683656</DOCNO>
	<brief_summary>HIV-infected patient increase risk cardiovascular disease . Large investigation support inverse correlation HDL-C level coronary heart disease . Therefore treatment lower HDL-C niacin could reduce risk atheroprogression benefit term lipid profile , also reduce atherosclerotic inflammation . The study aim show therapy target HDL-C increase HIV-infected patient suppressive cART potential reduce subclinical atherosclerotic inflammation associate HIV HIV-individuals cART . NILACH randomise , multicenter , double blind , placebo control , 48 week trial test effect newly market niacin/laropiprant carotid intima-media thickness ( IMT ) 90 subject . - Regimen 1 : ER niacin/laropiprant 1g/20 mg first 4 week 2g/40mg week 5 end study ( titration aim reduce adverse reaction ) - Regimen 2 : ER niacin/laropiprant placebo p.m . The primary end point change mean common carotid intima-media thickness baseline 48 week , compare niacin/laropiprant group placebo group . The propose vivo experiment provide insight potential benefit niacin treatment cardiovascular disease HIV patient . In addition , able clarify role systemic inflammatory mediator development early atherosclerosis HIV-infected patient antiretroviral therapy . Detection treatment non-infectious co-morbidities cardiovascular disease become essential HIV-infected individual expose lifelong antiretroviral therapy go beyond mere management opportunistic infection virologic suppression .</brief_summary>
	<brief_title>ER Niacin/Laropiprant Impact Cardiovascular Markers Atheroprogression HIV-infected Individuals cART</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Adult patient &gt; 40 year ; Women childbearing potential must use two reliable contraceptive method entire trial , day 1 one month end trial . Signing study consent form ; Stable cART since least 3 month ( ie recent drug change ) ; HIVRNA 100 copy least 6 month ; HDLcholesterol &lt; 1.29 mmol/l men ; &lt; 1.42 mmol/l woman Pregnancy lactation ; Congestive Heart Failure ; Malignant Hypertension ; Acute chronic coronary artery disease ; Any know cardiac arrhythmia ; Diabetes ; Concomitant cancer , rheumatologic disease inflammatory bowel disease ; Concomitant renal hepatic disease : Creatinine 150 micromol/L Transaminases 5 time upper normal limit Prothrombin time ( Quick ) value 50 % ; Prior intolerance niacin therapy ( report medical report ) ; Cyclosporine , antiinflammatory drug ( aspirin ) cytokine therapy concomitant intake ; Abnormal thyroid function ; Excessive consumption alcohol ; Known severe lactose intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Niacin/laropiprant</keyword>
	<keyword>HDL</keyword>
</DOC>